Innovation Pharmaceuticals Inc (IPIX)

[Stan Dango]

3 scenarios for these in-vitro studies at the RBLs

1) B has no effect on covid during these in-vitro studies. IPIX is bankrupt and trades below a nickel, if that.
2) B has some mild positive effect on covid, but not enough to warrant further studies or attract interest from larger pharmaceutical companies. IPIX is bankrupt and trades between a nickel and a dime. A minuscule chance exists that another company acquires the rights to B for one of its original purposes based on data garnered from the RBL studies. B has experienced this scenario already with meeting its phase 2 goals for trials with OM but with not good enough results to attract funding for a phase 3 trial.
3) B has a statistically significant effect on covid and advances into human trials. IPIX is still bankrupt so a larger pharma company partners with IPIX for a majority control of revenue from B if it succeeds, or a few potential partners lie in wait for the human trial results, or someone just buys it outright. IPIX likely trades between .25 and 1.00.

If there is good news, the PR will most likely be released before 830am on that day (most covid-related companies seem to be putting them out around 7am or as early as possible). Bad news will come right at 930am or just after the bell.

It’s important to realize this stock is a lottery ticket and we’re all hoping for scenario 3. Scenario 2 and 1 are most likely (as they are with most clinical stage biooharma drugs - most fail) but scenario 3 means a promising drug for covid patients and $ for shareholders.